Prefoldin (PFDN) is a co-chaperone protein that is primarily known for its classic cytoplasmic functions in the folding of actin and tubulin monomers during cytoskeletal assembly. Here, we report a marked increase in prefoldin subunit 1 (PFDN1) levels during the transforming growth factor (TGF)-β1-mediated epithelial-mesenchymal transition (EMT) and in human lung tumor tissues. Interestingly, the nuclear localization of PFDN1 was also detected. These observations suggest that PFDN1 may be essential for important novel functions. Overexpression of PFDN1 induced EMT and cell invasion. In sharp contrast, knockdown of PFDN1 generated the opposite effects. Overexpression of PFDN1 was also found to induce lung tumor growth and metastasis. Further experiments showed that PFDN1 overexpression inhibits the expression of cyclin A. PFDN1 suppressed cyclin A expression by directly interacting with the cyclin A promoter at the transcriptional start site. Strikingly, cyclin A overexpression abolished the above PFDN1-mediated effects on the behavior of lung cancer cells, whereas cyclin A knockdown alone induced EMT and increased cell migration and invasion ability. This study reveals that the TGF-β1/PFDN1/cyclin A axis is essential for EMT induction and metastasis of lung cancer cells.
INTRODUCTION
Lung cancer has become one of the most prevalent and lethal cancers worldwide, and metastasis is the main cause of its high mortality rate in patients. 1 Detachment from the primary loci and the invasion of cancer cells into the surrounding tissues can be initiated by the loss of cell-cell adhesion and the gain of motility and invasive properties. 2 During the past decade, mounting data have shown that epithelial-mesenchymal transition (EMT) is a critical factor contributing to the invasion and distal metastasis of many epithelial-originated cancers. EMT has been characterized to be a fundamental biological event that has important roles in embryonic development, wound healing, chronic fibrosis and cancer metastasis. 3 EMT causes the reorganization of the cytoskeleton and endows epithelial cells with a mesenchymal phenotype, which is important for mediating changes in cell identity and behavior. Various factors have been implicated in the control of EMT. Transforming growth factor (TGF)-β1 is one of the strongest inducers of EMT and receives abundant attention owing to its potent pleiotropic effects implicated in a variety of pathophysiological processes, including cancer progression. 4 An increasing number of molecules have been identified to be involved in TGF-β1 signaling and associated cellular and biological events. Insulin receptor substrate-1, 5 forkhead box transcription factor A2, 6 and hepatocyte nuclear factor 6 7 were shown to be potent EMT suppressors. They are essential for maintaining the epithelial phenotype and are therefore important in the inhibition of EMT and its associated cellular events. Decreased expression levels of these molecules have been linked with TGF-β1-induced EMT, growth and metastasis of lung cancers. In contrast, prostate transmembrane protein, androgen induced-1 is important for the plasticity of epithelial cells and its significant increase is required for TGF-β1-induced EMT in lung cancer cells. 8 These findings suggest that a TGF-β1 signaling network is orchestrated to regulate the equilibrium between the epithelial and mesenchymal properties of various cells, which impacts cell fates and behavior decisions. Further investigation into the relevant aspects of TGF-β1 signaling is important for deepening our understanding of EMT and could provide more precise mechanism-based clinical treatment of some cancers.
Chaperone proteins have been shown to be involved in cancer development and progression. 9, 10 However, little is known about their roles in TGF-β signaling and the induction of EMT. It has been shown recently that chaperone proteins are involved in the induction of EMT and the metastasis of prostate cancer cells. 11, 12 Until recently, the roles of co-chaperones in TGF-β-induced EMT and other relevant patho-physiological processes were poorly understood. Prefoldin (PFDN) is a co-chaperone protein that captures unfolded polypeptides and transfers them to the chaperonin containing tailless complex polypeptide-1. 13 PFDN exists in the cytosol as a complex containing six subunits. The involvement of PFDN subunits in cancer progression has been reported in several publications. PFDN subunits can interact with HDAC1 with high affinity in HepG2 hepatocarcinoma cells. 14 PFDN4, a subunit of the PFDN complex, is decreased in colorectal cancer and is involved in the inhibition of cell growth and invasiveness. 15 Prefoldin subunit 1 (PFDN1) is important in cytoskeletal rearrangement, as the phenotypes caused by PFDN1 depletion were all consistent with that of abnormal cytoskeletal functions. 16, 17 Considering these findings and the close relationship between cytoskeletal rearrangement and EMT, we hypothesized that PFDN1 is an essential factor involved in the regulation of EMT and its accompanying biological events.
Cyclin A (also known as cyclinA2) is important in cell cycle regulation and is implicated in cell fate determination. Cyclin A depletion was shown to cause an increase in cytoskeletal rearrangement and cell migration in normal mammary epithelial cells. 18 Compared with low invasive or primary tumors, the expression level of cyclin A is markedly lower in a highly invasive colon adenocarcinoma cell line, suggesting that loss of cyclin A is linked to tumor metastasis. 19 Cyclin A knockdown was recently reported to induce EMT in transformed mammary epithelial cells. 20 However, the mechanism underlying the regulation of cyclin A expression and the involvement of cyclin A in the EMT of other tumor types remains poorly understood.
In this study, we investigated the link between PFDN1 and TGF-β1 signaling, the roles of PFDN1 and its regulatory effect and mechanism of suppressing cyclin A expression during human lung cancer progression. PFDN1 levels can be increased by TGF-β1 stimulation, which promotes migration, invasion, xenograft growth and the metastasis of lung cancer cells. These effects were mediated through the transcriptional inhibition of cyclin A by PFDN1 and the subsequent induction of EMT and associated changes in cell behavior. Our findings underscore the importance of PFDN1 in TGF-β1 signaling and EMT induction linked with lung cancer development and progression.
RESULTS
Increases in PFDN1 levels in tumors and TGF-β1-induced EMT In identifying novel molecules implicated in TGF-β1-mediated EMT in A549 and H358 lung cancer cells (Figure 1a) , we observed that PFDN1 levels were markedly increased in both time-and dosedependent manners (Figure 1b and Supplementary Figure S1a) , suggesting that PFDN1 may be involved in EMT and tumor progression. The basal expression levels of PFDN1 in H446 and H1299 are much higher than that in HCC827 human lung cancer cells. PFDN1 levels in A549 and H358 lung cancer cells were moderate. Interestingly, PFDN1 levels are correlated positively and negatively with their degrees of mesenchymal and epithelial phenotypes, respectively (Figure 1c ). Consistent with these findings, PFDN1 levels are also correlated with the invasion ability of these cells (Figure 1d ). These results suggest that PFDN1 is essential for the mesenchymal phenotype and for the induction of EMT. Analysis of the online Oncomine database revealed that PFDN1 is highly expressed in some tumors (Figure 1e ). In addition, PFDN1 is significantly increased in human lung adenocarcinomas ranging from Stage I to Stage III (Figure 1f ), suggesting that increased PFDN1 expression is closely associated with the development of lung tumors. No change in the mRNA level of PFDN1 was observed in response to TGF-β1 (Supplementary Figure S1b) . Treatment of cells with a proteasome inhibitor (MG132) also had no obvious effect on the TGF-β1-mediated increase in PFDN1 expression levels (Supplementary Figure S1c) . However, inhibition of protein synthesis by cycloheximide abolished the increase in PFDN1 induced by TGF-β1 (Supplementary Figure S1d) . These data suggest that the TGF-β1-induced increase in PFDN1 occurs at the translational level.
PFDN1 promotes EMT and associated events in lung cancer cells To determine the role of PFDN1 in EMT and EMT-related cell processes, we generated PFDN1-overexpressing lung cancer cell lines. PFDN1 overexpression induced EMT in A549 and H358 cells, as determined by E-cadherin and N-cadherin levels ( Figure 2a PFDN1 knockdown inhibits EMT and cell motility in lung cancer cells To verify the role of PFDN1, we generated PFDN1-knockdown lung cancer cell lines (Figure 3a) . PFDN1 knockdown inhibited TGF-β1-induced EMT, as determined by morphological changes (Figure 3b ), E-cadherin and N-cadherin levels (Figure 3c ), and cell migration (Figure 3d ). PFDN1 knockdown alone also significantly reduced mesenchymal marker protein levels (Supplementary Figure S2a and b) . Consistent with these data, PFDN1 knockdown abrogated TGF-β1-induced cell migration (Figures 3e and f) and reduced the anchorage-independent growth of cells (Figure 3g ). These results verify the notion that PFDN1 has an important role in EMT and EMT-associated changes in cell behavior.
PFDN1 promotes the growth and metastasis of lung cancer cells PFDN1-mediated EMT and relevant cell events suggest its important roles in cancer progression. PFDN1 overexpression increased the growth of xenograft lung cancer cells (Figures 4a  and b ) and the lung metastatic nodule size (Figures 4c and d) . The sizes of metastatic areas with larger metastatic nodules were also found to be increased (Figure 4e ). The survival of cancer cells by increased resistance to anoikis in the circulating blood is a critical step in the formation of distal metastases, which is indicated by the presence of circulating tumor cells (CTCs) in blood. As shown in Figure 4f , PFDN1 overexpression significantly increased the level of CTCs in blood. These results demonstrate that PFDN1 can function as a lung cancer promoter.
PFDN1 functions as a transcriptional suppressor of cyclin A Although the nuclear location and function of PFDN1 in yeast has been reported, 21 there are no publications reporting the existence of nuclear PFDN1 in mammalian cells. Interestingly, PFDN1 can be detected in both the cytoplasm and the nucleus. TGF-β1 treatment significantly increased the level of nuclear PFDN1, as determined by immunofluorescent staining (Figure 5a ) and immunoblotting ( Figure 5b ). The nuclear location of PFDN1 suggests that PFDN1 may have novel functions in addition to its cytoplasmic role in the assembly of cytoskeleton. PFDN1 overexpression has an inhibitory effect on the proliferation rate of lung cancer cells (Supplementary Figure S3) . PFDN1 overexpression significantly reduced both the mRNA ( Figure 5c ) and the protein levels ( Figure 5d ) of cyclin A, whereas PFDN1 knockdown upregulated the mRNA ( Figure 5e ) and protein levels of cyclin A (Figure 5f ). The upregulation of cyclin A by PFDN1 knockdown was also observed in H358 and H1299 cells (Supplementary Figure S4a and b) . In addition, TGF-β1 treatment also reduced cyclin A expression at both the mRNA and protein level (Supplementary Figure S5a and b) . These results suggest that cyclin A is a downstream target of PFDN1. PFDN1 and PFDN4 have a similar molecular structure, 22, 23 and PFDN4 is a transcription factor that regulates the cell cycle. 24 Moreover, the detection of nuclear PFDN1 suggests its function as a transcriptional regulator. PFDN1 overexpression inhibited the promoter activity of cyclin A in both A549 ( Figure 5g ) and H358 cells (Figure 5h ). The sequence from − 210 bp to 364 bp in the promoter region of cyclin A was essential for PFDN1-mediated suppression of its promoter activity. We performed a Chromatin Immunoprecipitation assay revealing that PFDN1 interacts directly with the promoter of cyclin A around the transcriptional start site (Figures 5i and j) . These results indicate that PFDN1 can function as a transcriptional suppressor of cyclin A.
Cyclin A suppresses the PFDN1-induced EMT and cell migration The transcriptional suppression of cyclin A by PFDN1 suggests that cyclin A is important for maintaining the epithelial phenotype of cells. Cyclin A knockdown alone induced EMT as determined by changes in cell morphology (Figure 6a ), EMT markers suppressed the growth of metastatic tumors induced by PFDN1 overexpression, as indicated by representative lung images and hematoxylin and eosin staining (Figure 8d ), lung weight ( Figure 8e ) and relative metastasis area (Figure 8f ). The PFDN1-mediated increase in CTCs was also abrogated by cyclin A overexpression (Figure 8g ). To summarize our findings, a schematic illustration is provided (Figure 8h ). The expression level of PFDN1 is significantly increased in lung tumors and in TGF-β1-induced EMT. PFDN1 can also be found in the cell nucleus, where it plays a role in transcriptional regulation. Nuclear PFDN1 binds TGF-β-PFDN1-cyclin A in tumor progression D Wang et al and interacts with the cyclin A promoter at its transcriptional start site, which suppresses the expression of cyclin A and leads to EMT and increased invasion and metastatic growth of lung cancer cells. DISCUSSION PFDN1, a small molecule of 14 kDa, is an important subunit of the PFDN complex. Eukaryotic PFDN possesses two α subunits (PFDN3 and PFDN5) and four β subunits (PFDN1, PFDN2, PFDN4 and PFDN6). 25 In addition to their roles in the PFDN complex, individual PFDN subunits have been shown to possess other functions. For instance, PFDN3, PFDN4 and PFDN5 have been identified as transcriptional regulators. 24, 26, 27 PFDN3 and PFDN5 subunits have been shown to form complexes with proteins other than chaperones. 28, 29 The involvement of different PFDN subunits in cancer-related biological events has been reported in the past several years. These subunits include the PFDN2, PFDN3, PFDN4, PFDN5 and PFDN6. 15, [30] [31] [32] [33] As PFDN1 is significantly increased during TGF-β1-induced EMT in lung cancer cells, we hypothesized that PFDN1 may also be linked with lung cancer development and progression, and this was supported by our results. Our studies revealed that PFDN1 is an essential contributing factor in the transcriptional repression of cyclin A expression and the induction of the mesenchymal phenotype. Although it has been shown that PFDN subunits can have individual roles outside of the PFDN complex, it is not clear if the involvement of PFDN1 in tumor development and progression are complex-dependent.
Tumor growth is an outcome influenced by multiple factors, such as cell proliferation, cell survival, the tumor microenvironment and angiogenesis. [34] [35] [36] Growth arrest is generally regarded as a precondition for cell differentiation and transdifferentiation. 37 It has become increasingly clear that the induction of EMT generally presupposes cell growth arrest or decelerated proliferation, which is particularly prominent in TGF-β1-induced EMT in non-cancer cells. For instance, TGF-β1-induced EMT is highly correlated with growth arrest in Mv1Lu and AML12 cells. 38, 39 The finding that PFDN1 induces EMT and inhibits cell proliferation also suggests a link between cell growth arrest and the induction of EMT. EMT also confers cells with anoikis resistance, which is important for anchorage-independent growth in soft agar and for the survival of CTCs in the blood. This is likely a major factor contributing to the increased metastatic growth of lung cancer cells induced by PFDN1 overexpression. The fact that PFDN1 promotes anchorage-independent proliferation, increased CTC levels, growth and the metastatic formation of lung tumors suggests that PFDN1 is a pro-survival factor for lung cancer cells.
The finding of PFDN1 in both the cytosol and nucleus and our data indicating that PFDN1 levels can be significantly increased by TGF-β1 during EMT induction imply that PFDN1 may have independent and different roles in the cytosol and nucleus. The cytoplasmic and nuclear functions of PFDN1 may also be coupled in a way as to favor cytoskeleton dynamics and cell homeostasis, which has been suggested by other published findings. 40 It has been reported that dynamic reorganization of actin is linked with the morphology, migration and invasion of cancer cells. 41, 42 Tubulin has been shown to be essential in cell-cell adhesion formation and EMT. 43, 44 In addition, the nuclear function of PFDN in eukaryotes has been reported. Nuclear PFDN4 was found to act as a transcription factor. 24 PFDN5 was shown to be involved in the transcriptional repression of c-MYC. 27 The function of nuclear PFDN1 in yeast has been reported, 45 but the function of nuclear PFDN1 in mammalian cells was previously unknown. This study revealed a role for nuclear PFDN1 as a transcriptional suppressor.
The findings that PFDN1 increases the viability of lung cancer cells and induces growth arrest at G0/G1 phase imply a relationship between the role of PFDN1 and cell cycle control, which is also consistent with the cell cycle-dependent induction of EMT by TGF-β1. 39 It has been reported that the expression of cyclin A during G1 phase is very low and is induced upon entry into S phase. [46] [47] [48] In addition, downregulation of cyclin A has been reportedly linked with cell cycle arrest at G0/G1, the resistance to anoikis and the control of cell motility and invasiveness. 20, 49, 50 Thus, we hypothesized that PFDN1 acts through cyclin A to control EMT and the invasive and metastatic growth of lung cancer cells, which was verified by further investigations. The present study showed that PFDN1 downregulates cyclin A through transcriptional suppression of cyclin A expression. As a cell cycle regulator, cyclin A functions as a critical element in both TGF-β1-and PFDN1-mediated EMT and EMT-related lung cancer progression. As cyclin A can block PFDN1-induced growth, metastasis and tumorsphere formation of lung cancer cells, cyclin A may function as a potent suppressor of lung cancer progression. Cyclin A levels are significantly higher in human primary colorectal tumors than their corresponding metastases, 19 which also suggest that cyclin A is a tumor suppressor. Because TGF-β1 induces sustained and significant increases in PFDN1 levels and TGF-β1-induced EMT is dependent on PFDN1, these results also suggest that PFDN1 can function in both TGF-β-dependent and -independent manners. Our data also suggest a novel molecular link between TGF-β signaling and lung cancer development and progression.
The findings that PFDN1 is highly expressed in several types of tumor tissues (Figure 1e ) and breast cancer cells (Supplementary Figure S9) suggest that PFDN1 promotes lung cancer progression. The fact that PFDN1 is significantly increased in all the stages of lung cancer cells (Figure 1f ) and that PFDN1 promotes tumor growth and lung cancer metastasis (Figure 4 ) suggest that PFDN1 is involved in the early stage of lung cancer development. PFDN1 overexpression induces the formation of larger tumorspheres of lung cancer cells (Supplementary Figure S10a and b) , indicating that PFDN1 overexpression enhances the self-renewal property In summary, our data show that PFDN1 is significantly increased in lung cancers. Increased expression of PFDN1 is also associated with TGF-β1-induced EMT and EMT-related changes in cell behavior. PFDN1 functions as a tumor promoter that stimulates the invasive growth and distal metastasis of lung cancer cells via EMT induction. PFDN1 was also detected in the nuclei of cancer cells. Nuclear PFDN1 binds with and suppresses the promoter activity of cyclin A, causing transcriptional downregulation of cyclin A expression. The suppression of cyclin A expression reduced the proliferation rate of lung cancer cells, promoted their EMT, and increased cell migration and resistance to anoikis, causing invasive growth and distal metastasis of lung cancer cells. Thus, PFDN1 may be an important candidate target molecule for potential consideration in clinic diagnosis and treatment of lung cancers.
MATERIALS AND METHODS
Cell culture A549, H358, HCC827, H446 and H1299 human lung cancer cells and HEK293T cells were purchased from the American Type Culture Collection (Manassas, VA, USA). A549 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (Thermo Scientific Hyclone, Rockford, IL, USA) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin (Life Technologies Gibco, Grand Island, NY, USA). H358, HCC827, H446 and H1299 were cultured in RPMI medium 1640 (Thermo Scientific Hyclone) containing the same supplements. All cells were incubated in a humidified atmosphere with 5% CO 2 at 37°C.
Reagents
Human recombinant TGF-β1 was purchased from Chemicon (Millipore, Billerica, MA, USA). MG132 (M7449) and cycloheximide (46401) were purchased from Sigma (St Louis, MO, USA). Matrigel matrix (356231) was purchased from BD Biocoat (Franklin Lakes, NJ, USA). Lentivirus system plasmids pCDH-CMV-MCSEF1-Puro, Δ8.9, pVSVG, psPAX2, pMD2.G and pLKO.1-TRC were purchased from Addgene (Cambridge, MA, USA). Antibody information is listed in supplementary Table S1. RNA isolation and real-time PCR PCR assays were conducted as previously described. 7 All values were normalized against the glyceraldehyde-3-phosphate dehydrogenase. The primers used for real-time PCR are listed in supplementary Table S2 .
Plasmid construction and RNA interference assays
The primers used for amplification of homo PFDN1 and cyclin A are listed in supplementary table S3. Both human PFDN1 and cyclin A were generated by ligating the full-length open-reading frame into the pCDHPuro-IRES-GFP vector (Addgene). For knockdown of PFDN1 and cyclin A, several independent small hairpin hRNA sequences targeting these proteins were ligated into pLKO.1 vectors (Addgene), with a scrambled small hairpin RNA sequence serving as the control. Small hairpin RNA sequences are listed in Supplementary Table S4 .
Stable transfection
High-titer lentivirus was packaged in HEK293T cells using calcium chloride transfection. Viral supernatants were collected twice at 24 h intervals after transfection, filtered and applied to lung cancer cells in the presence of 10 μg/ml polybrene for 16 h. Cells were selected with puromycin for at least 1-2 weeks. Gene overexpression and gene knockdown were confirmed by immunoblotting using specific antibodies.
Preparation of cell lysates and western blotting
Cell lysates were prepared and western blots were performed as previously described. 51 β-actin or β-tubulin was used as a loading control.
Preparation of subcellular fractionation Subcellular fractionation was performed as previously described. 51 Immunofluorescent staining
Cells were cultured on glass slides and immunofluorescent staining was performed as previously described. 8 Immunohistochemistry staining
Thirty pairs of human lung carcinoma tissues and the relevant adjacent tissues were purchased from Outdo Biotechnology (Shanghai, China). The product ID of the tissue microarray is HLug-Ade 060PG-01. This assay was performed as previously described. 8 Cell migration assays A transwell assay and wound-healing assay were used to determine cell migration ability. The assays were performed as previously described. 8 Cell invasive migration assay
The cell invasion assay was performed using Transwell migration chambers (8 μm pore size; Corning Costar, NY, USA) according to the vendor's instructions as previously described.
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Soft agar assay A soft agar assay was used to determine the anchorage-independent growth of cells, as previously described. 7 Animal experiments
Female athymic BALB/c nude mice (4-6 weeks of age) were purchased from Shanghai Laboratory Animal Center (Shanghai, China). All animal experiments were conducted as previously described, 52 which are under the ethical guidelines of the Institute of Biochemistry and Cell Biology. Mice were randomly separated into each group, independent samples were collected from groups of at least five mice, and all experiments were performed at least three times. Animals were euthanized and excluded from the analysis when one of the following signs of morbidity was observed: significant tumor ulceration (41 cm), severe injure that induce secondary infection and dehydration and inability to move, feed and defecate.
Detection of circulating tumor cells
The assay was performed as previously described. 52 The relative amount of CTCs was examined by detecting the ratio of human glyceraldehyde-3-phosphate dehydrogenase expression to mouse glyceraldehyde-3-phosphate dehydrogenase expression by real-time quantitative PCR. The primers used for this assay are listed in supplementary Table S2 .
Luciferase reporter assay
The human cyclin A promoter (containing 1 GC box and 1 TATAAT box) was cloned into the pGL3 basic firefly luciferase vector (Thermo Scientific) and then transfected into PFDN1-overexpressed cells. The specific primers for promoter sequences are listed in supplementary Table S5 . Cell lysates were prepared 24 h after transfection in reporter lysis buffer (Promega, Madison, WI, USA) and luciferase substrate was added. The luciferase activity was recorded on a luminometer (Veritas, Promega).
Chromatin immunoprecipitation assay
The assay was performed with an EZ-Zyme Chromatin Prep Kit (Millipore), according to the manufacturer's protocol. 52 Anti-PFDN1 antibody was used to precipitate DNA cross-linked with PFDN1, and normal rabbit IgG was used in parallel as a control. Enriched DNA was then used as a template to assess the binding intensity of PFDN1 to putative binding sites in the cyclin A promoter. Primers used in this assay are listed in supplementary  Table S2 .
Cell cycle analysis
Cells were trypsinized and gently collected and fixed with 70% ethanol overnight at − 20°C. After washing with phosphate-buffered saline TGF-β-PFDN1-cyclin A in tumor progression D Wang et al containing 20 mM EDTA, cells were treated with 0.1 mg/ml RNase A for 1 h at 37°C and were then stained with 0.1 mg/ml propidium iodide. The DNA content of cells was measured using flow cytometry (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ, USA).
Ethical approval
All animal experiments were performed in accordance with a protocol approved by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Approval Number: SIBCB-NAF-15-002-S305-021). The lung cancer tissue chip (Hlug-Ade 060PG-01) was purchased from Shanghai Outdo Biotechnology Company. The archived samples from Shanghai National Engineering Research Center for the biological chromatin Immunoprecipitation assay were anonymous, and informed consent was not required.
Statistical analysis
All samples used for statistical analysis were from at least three independent experiments performed in duplicates or up to five parallel controls. For experiments with two groups, statistical significance was determined by Student's t-test. For experiments with more than three groups, statistical analyses were performed with analysis of variance followed by post hoc pairwise comparisons. The data shown are means ± s.d. of three independent experiments. The P-value of o 0.05 was considered statistically significant. The P-values were designated as *P o 0.05, ** P o 0.01, *** P o 0.005. n.s., non significant.
